Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer identifier:
NCT04895722 (

Stage 4 colorectal cancer

Study Contact Information:

For additional information, please contact:

Merck Clinical Trials toll free Number: 1-888-577-8839 
or email: [email protected]

About the Study

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus four other treatments in patients with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic (stage IV) Colorectal Cancer.

This is phase 2, multi-arm, randomized, open-label study.  Participants are placed into one of the five study groups by chance. All study participants will know which medication they are receiving during the study. 

What the Study Involves

Participants in this study will receive one of the following five therapies for up to approximately 2 years.    

Study participants will be followed for up to 39 months.

Study Locations








This Study is Open To:

People age 18 years or older who meet the following criteria:

Either one of the following two criteria also needs to be met:

  1. has previously been treated for cancer and the disease progressed. Prior treatment must have included a specific set of therapeutic agents to be considered eligible for this study. The study team will review the lists of required agents with the patient during enrollment.  
  2. Cancer has not been treated, including no prior chemotherapy or immunotherapy for the disease.

This Study is Not Open To:

People with the following are not eligible for the study:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.